Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial

Keyphrases

• Cardiovascular Risk 100%
• Monotherapy 100%
• Pulmonary Arterial Hypertension 100%
• Clinical Failure 66%
• Failure Event 50%
• Initial Combination Therapy 50%
• Combination Therapy 33%
• Confidence Interval 33%
• Left Ventricular Dysfunction 33%
• Hazard Ratio 33%
• Multiple Risk Factors 33%
• Ambrisentan 33%
• Tadalafil 33%
• Diabetes 16%
• Tolerability 16%
• Adverse Events 16%
• Low Dose Rate 16%
• Hypertension 16%
• Clinical Response 16%
• Once-daily 16%
• Comorbidity 16%
• Treatment Effect 16%
• 6-minute Walk Distance (6MWD) 16%
• Low-magnitude 16%
• Treatment-naïve Patients 16%
• Drug Withdrawal 16%

Medicine and Dentistry

• Cardiovascular Risk 100%
• Pulmonary Hypertension 100%
• Monotherapy 100%
• Combination Therapy 83%
• Left Ventricular Diastolic Dysfunction 33%
• Hazard Ratio 33%
• Ambrisentan 33%
• Tadalafil 33%
• Diabetes 16%
• Adverse Event 16%
• Comorbidity 16%
• Treatment Effect 16%
• Drug Withdrawal 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Cardiovascular Risk 100%
• Monotherapy 100%
• Pulmonary Hypertension 100%
• Combination Therapy 83%
• Ambrisentan 33%
• Left Ventricular Diastolic Dysfunction 33%
• Tadalafil 33%
• Adverse Event 16%
• Tolerability 16%
• Comorbidity 16%